ChoiteC Pharmaceutical R&D Center (Nanjing) r&d strategy to solve the clinical needs of urgent drugs as its own responsibility, green production oriented; The combination of imitation and innovation, independent development and technology introduction. Through independent research and development, the company has built domestic advanced enzymatic reaction technology platform and microchannel reaction technology platform, and formed strong development capacity and coverage of emergency drugs through cooperative research and development.

Our company has established a good cooperative relationship with China Pharmaceutical University, ***** Pharmaceutical Technology Co., Ltd. and other scientific research institutions and CRO companies to cooperate in drug prescription development and quality research. The projects developed through this model include BM_R01_DL, BM_R02_ST, BM_R03_TM and other pediatric drugs.

At the same time, our company has established good cooperative relations with several pharmaceutical manufacturers in **, **, ** and other places, and carried out cooperation in the commissioned production of research varieties under the framework of MAH (Marketing licensor) system. A quality assurance and pharmacovigilance system covering the whole life cycle of drugs after they are put on the market has been planned to fulfill the main responsibilities of the marketing licensor.